FACULTY
Nirmala Gonsalves, MD, AGAF, FACG
Professor of Medicine
Co-director Northwestern Eosinophilic Disorders Program
Division of Gastroenterology and Hepatology
Northwestern University
Feinberg School of Medicine
Chicago, IL
PROGRAM OVERVIEW
This RESTORE gamification enduring activity will focus on the epidemiology, pathophysiology, diagnosis, and treatment of eosinophilic esophagitis (EoE). In addition, it will help healthcare professionals who care for patients with EoE improve their ability to diagnose the condition and to provide individualized treatment based on current guidelines, recent clinical data, and patient characteristics.
TARGET AUDIENCE
This educational activity is designed for gastroenterologists, allergists, immunologists, ENT specialists, emergency physicians, and other members of the multidisciplinary team to ensure optimal patient outcomes in the management of EoE.
LEARNING OBJECTIVES
- Summarize the role of type 2 inflammation in the pathophysiology of eosinophilic esophagitis and challenges in diagnosis.
- Appraise off-label therapies and deficiencies in management of eosinophilic esophagitis.
- Evaluate current clinical data concerning the use of novel therapies targeting type 2 inflammation in eosinophilic esophagitis.
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Gonsalves discloses that she has received royalties from UpToDate, consulting fees from Allakos, AbbVie, AstraZeneca, Nutricia, Knopp, BMA, Sanofi-Regeneron, and Takeda. Dr. Gonsalves has served on the speakers’ bureau for Takeda and Sanofi-Regeneron.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Debra Gordon, Medical Director of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME information and faculty disclosures
- Participate in the enduring activity
- Submit the evaluation form to Med Learning Group
You will receive your certificate upon completion as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.